|
Comparison of Samara DOTS cohort with overall treatment success and outcome for global DOTS cohorts in 2002 |
||||
| % |
Died |
Failed |
Defaulted |
Treatment success |
|
|
||||
| Samara, Russia |
3.6 |
2.2 |
5.1 |
75.3 |
| Eastern Europe |
6.7 |
8.8 |
6.4 |
74.9 |
| Central europe |
5.0 |
3.5 |
6.0 |
79.7 |
| East Mediterranean |
3.2 |
1.4 |
7.8 |
83.5 |
| Established markets |
9.7 |
2.4 |
2.6 |
76.5 |
| Latin America |
4.3 |
1.2 |
6.0 |
83.4 |
| Southeast asia |
3.9 |
2.5 |
6.4 |
85.1 |
| Western Pacific |
2.2 |
0.9 |
2.2 |
89.1 |
|
Established markets include member states of the EU, North America, Australia, New Zealand and Japan. | ||||
Balabanova et al. Respiratory Research 2006 7:44 doi:10.1186/1465-9921-7-44 |
||||